system treatment aids-rel kaposi sarcoma result random trial purpos patient acquir immunodefici syndrom aid epidem kaposi sarcoma chemotherapi due myelosuppress patient risk infect surviv multi-cent random clinic trial single-ag combin chemotherapi advanc aids-rel kaposi sarcoma low-dos chemotherapi role combin therapi diseas toxic intens patient method sixty-on patient extens mucocutan kaposi sarcoma viscer involv treatment low-dos adriamycin doxorubicin case combin bleomycin vincristin abv case patient strata prognost featur surviv prior studi treatment arm studi entri result complet partial tumor remiss abv adriamycin median surviv month group studi entri criteria surviv lymphocyt level g/dl histori constitut symptom prior histori opportunist infect similar arm regimen neutropenia granulocyt count patient adriamycin patient abv progress success cours chemotherapi treatment arm develop aids-defin opportunist infect infrequ therapi conclus low-dos abv effect chemotherapi regimen treatment extens kaposi sarcoma abv chemotherapi respons adriamycin accept toxic 